全球药品製造市场-市场规模、份额、成长分析：依药物、製造流程（原料药製造、成品製造）、依治疗领域分类-产业预测（2023-2030）

Global Pharmaceutical Manufacturing Market Size, Share, Growth Analysis, By Drug, By Manufacturing process(Active pharmaceutical ingredient manufacturing, finished dosage form manufacturing), By Therapeutic area - Industry Forecast 2023-2030

出版日期: 2023年09月20日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球药品製造市场规模为4,259亿美元。预测在预测期（2023-2030年），该市场将以15.9%的年复合成长率扩张，从2023年的5721亿美元增长到2030年的16071.6亿美元。

全球药品製造市场作为医疗保健领域至关重要的部门继续蓬勃发展。该市场位于研究、开发和药品製造领域，是由多种要素共同推动的。其中包括世界人口的成长、慢性病的增加、医疗技术的进步。对新药、个人化医疗和生物製药的需求是市场扩张的强大驱动力。此外，医疗保健基础设施的普及、旨在改善医疗保健可及性的政府配合措施以及对製药设施投资的增加也促进了整个市场的强劲增长。但值得注意的是，市场的发展并非没有挑战。严格的法规、与定价相关的压力以及与智慧财产权相关的复杂性都是可能阻碍整体市场发展的潜在障碍。

全球药品製造市场的促进因素是全球对医疗保健产品和药品解决方案不断增长的需求。世界人口的成长，加上慢性病和感染疾病的增加，导致药品需求大幅增加。此外，医疗技术的进步和高龄化正在协同增加对开创性药物和治疗方法的需求。为此，药品製造商被迫提高产能、投资研发并采用新颖的製造技术，以有效满足新兴市场不断增长的需求。

药品製造市场的一个重要阻碍因素是严格的法规环境。政府和法规机构制定严格的标准和基准，以确保药品的安全性、有效性和品质。遵守这些标准需要对基础设施、强大的品管框架和完整的文件进行大量投资。违反这些法规可能会导致严厉的处罚并损害公司的声誉。此外，复杂而冗长的新药核准流程可能会阻碍产品的快速推出，并延迟向患者提供关键药物。这些复杂的法规挑战为潜在的新参与企业设置了障碍，并增加了药品生产工作固有的整体成本和时间。

该报告研究了全球药品製造市场，并提供了市场概况，包括药物、製造流程、治疗领域、地区以及参与市场的公司概况的趋势。

主要企业简介
- Johnson & Johnson
- Pfizer Inc.
- Novartis International AG
- Roche Holding AG
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Amgen Inc.
- Bayer AG
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd

简介目录

Product Code: SQMIG35I2198

Global Pharmaceutical Manufacturing Market size was valued at USD 425.9 billion in 2021 and is poised to grow from USD 572.10 billion in 2023 to USD 1607.16 billion by 2030, at a CAGR of 15.9% during the forecast period (2023-2030).

The global pharmaceutical manufacturing market continues to flourish as a pivotal sector within the healthcare realm. Anchored in the realms of research, development, and the production of medicinal substances, this market is propelled forward by an amalgamation of factors. These encompass the upward trajectory of global population figures, the escalating incidence of chronic ailments, and the stride of medical technology's evolution. The impetus for novel pharmaceuticals, individualized medicinal approaches, and biologics acts as a formidable driving force that propels the market's expansion. Additionally, the proliferation of healthcare infrastructure, governmental initiatives aimed at enhancing healthcare accessibility, and the augmented investment in pharmaceutical manufacturing facilities collectively contribute to the robust growth of the market. Nonetheless, it's noteworthy that the market's progress is not devoid of challenges. Stringent regulations, pressures linked to pricing considerations, and complexities associated with intellectual property rights loom as potential hurdles that could impede the overall advancement of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Manufacturing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global pharmaceutical manufacturing industry can be segmented into various categories based on factors such as drug type, manufacturing process, therapeutic area, and geography. In terms of drug type, the industry encompasses the production of prescription drugs, over-the-counter medications, and biologics. The manufacturing process can be divided into active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, and packaging. Therapeutic areas covered by the industry include cardiovascular, oncology, central nervous system, respiratory, and infectious diseases. Geographically, the global pharmaceutical manufacturing sector is spread across major regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Driver

A catalyst propelling the global pharmaceutical manufacturing market is the escalating requisition for healthcare products and medicinal solutions on a global scale. The mounting worldwide populace, coupled with an uptick in chronic maladies and infectious ailments, has instigated a marked upswing in the demand for pharmaceutical interventions. Furthermore, progressions in medical technology and the prevalence of an aging demographic have synergistically augmented the call for pioneering pharmaceuticals and therapies. In response, pharmaceutical manufacturers are compelled to amplify their production capacities, channel investments into research and development endeavors, and embrace novel manufacturing technologies to effectively cater to the expanding market requisites.

Restraint

A prominent hindrance within the pharmaceutical manufacturing market stems from the exacting regulatory milieu. Governments and regulatory bodies institute stringent norms and benchmarks to ensure the safety, effectiveness, and caliber of pharmaceutical offerings. Adhering to these standards necessitates substantial investments in infrastructure, robust quality control frameworks, and meticulous documentation. Deviation from these regulations can lead to severe penalties and detriment to a company's repute. Furthermore, the intricate and time-intensive regulatory endorsement process for new medicinal agents can impede the swiftness of product introductions, thus prolonging the availability of vital medications to patients. These intricate regulatory challenges erect barriers for potential new entrants, thereby elevating both the overall expenses and the time frame intrinsic to pharmaceutical manufacturing endeavors.

Market Trends

A notable trend within the global pharmaceutical manufacturing arena is the escalating demand for personalized medicine and targeted therapeutic interventions. The advancements in technology and genomics have ushered in an era of precision-oriented and individualized treatments, prompting a transformation in pharmaceutical manufacturing dynamics, marked by a transition to smaller production batches and adaptable manufacturing procedures. Moreover, the pursuit of biologics and biosimilars has gained traction, propelled by the surge in chronic ailments and the necessity for groundbreaking therapies. Simultaneously, a pronounced emphasis on sustainability and ecologically conscious practices has taken root, with pharmaceutical manufacturers directing their efforts towards waste reduction, bolstering energy efficiency, and embracing environmentally friendly production protocols, aligning with both regulatory stipulations and consumer anticipations.